Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Influenza

Free Subscription 16.03.2026 1 Ann Intern Med 1 Antimicrob Agents Chemother 3 Antiviral Res 1 Biochem Biophys Res Commun 1 Cell 2 Epidemiol Infect 1 Eur J Epidemiol 1 J Epidemiol Community Health 2 J Gen Virol 2 J Infect 2 J Virol 2 JAMA 1 Lancet 2 MMWR Morb Mortal Wkly Rep 1 N Engl J Med 1 Pediatrics 1 PLoS Comput Biol 1 PLoS Med 31 PLoS One 2 Proc Natl Acad Sci U S A 13 Vaccine 6 Virology 1 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. LALANI HS, DiResta R, Baron RJ, Scales D, et al
   Addressing Viral Medical Rumors and False or Misleading Information.
   Ann Intern Med. 2023 Jul 18. doi: 10.7326/M23-1218.
   PubMed         Abstract available
   
   

   
   Antimicrob Agents Chemother

2. ZHENG X, You X, Liu Y, Wu B, et al
   Spatiotemporal dynamics and multiple driving factors of antimicrobial resistance in China during the COVID-19 pandemic (2019-2023): a provincial panel data analysis.
   Antimicrob Agents Chemother. 2026 Feb 9:e0160025. doi: 10.1128/aac.01600.
   PubMed         Abstract available
   
   

   
   Antiviral Res

3. ZHANG T, Wang ZL, Li XY, Luo RH, et al
   Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m(6)A enzymatic activity.
   Antiviral Res. 2026 Feb 19:106376. doi: 10.1016/j.antiviral.2026.106376.
   PubMed         Abstract available
   
   
4. YURGELONIS I, Rai DK, Li Z, Washington B, et al
   Analysis of Ibuzatrelvir's Activity Against SARS-CoV-2 Circulating Variants and In Vitro Resistance Mutations.
   Antiviral Res. 2026 Jan 30:106352. doi: 10.1016/j.antiviral.2026.106352.
   PubMed         Abstract available
   
   
5. TOSELLI F, Jacobs S, Scheers E, Jacobs T, et al
   Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals.
   Antiviral Res. 2026 Feb 9:106363. doi: 10.1016/j.antiviral.2026.106363.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

6. DEO S, Desai K, Patare A, Wadapurkar R, et al
   Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: Implication for mRNA therapies.
   Biochem Biophys Res Commun. 2023;680:108-118.
   PubMed         Abstract available
   
   

   
   Cell

7. YU S, Lin Y, Li Y, Chen S, et al
   Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine.
   Cell. 2023;186:4615-4631.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

8. FUNG IC, Liang H, Pierce KJ, Kraay ANM, et al
   Excess mortality in Mainland China after the end of the Zero COVID policy: A systematic review.
   Epidemiol Infect. 2026;154:e29.
   PubMed         Abstract available
   
   
9. AKBARIAN S, Sheikhi M, Khedri P, Baharifar N, et al
   The correlation between humoral immune responses and severity of clinical symptoms in COVID-19 patients.
   Epidemiol Infect. 2023;151:e158.
   PubMed         Abstract available
   
   

   
   Eur J Epidemiol

10. SLURINK IAL, de Boer AR, Bonten MJM, Sturkenboom MCJM, et al
    COVID-19 vaccination and short-term mortality risk: a nationwide self-controlled case series study in The Netherlands.
    Eur J Epidemiol. 2026;41:173-184.
    PubMed         Abstract available
    
    

    
    J Epidemiol Community Health

11. BEVILACQUA L, Fox-Smith L, Lewins A, Jetha P, et al
    Impact of COVID-19 on the mental health of children and young people: an umbrella review.
    J Epidemiol Community Health. 2023;77:704-709.
    PubMed         Abstract available
    
    

    
    J Gen Virol

12. NAZKI S, Tennakoon C, Reddy VRAP, Chen Y, et al
    Evaluating how infectious bursal disease virus (IBDV) infection influences influenza H3N8 challenge in chickens.
    J Gen Virol. 2026;107:002235.
    PubMed         Abstract available
    
    
13. DISLERS A, Nilova O, Jansons J, Skrastina D, et al
    Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant.
    J Gen Virol. 2026;107:002240.
    PubMed         Abstract available
    
    

    
    J Infect

14. ZHOU T, Zhang B, Zhang D, Jhaveri R, et al
    Pre-COVID-19 Body Mass Index and Postacute Cardiovascular, Gastrointestinal, and Neuropsychiatric Outcomes Among Children and Young Adults With SARS-CoV-2 Infection: An EHR-based Cohort Study from the RECOVER Initiative.
    J Infect. 2026 Feb 11:106702. doi: 10.1016/j.jinf.2026.106702.
    PubMed         Abstract available
    
    
15. WANG Z, Dunican C, Dayananda P, Ingar S, et al
    Comparative cross-species transcriptomics during RSV infection identifies targets to treat RSV disease.
    J Infect. 2026;92:106696.
    PubMed         Abstract available
    
    

    
    J Virol

16. FIELD CJ, Septer KM, Patel DR, Weaver VC, et al
    Defining the transmissible dose 50% for two pandemic influenza viruses in ferrets.
    J Virol. 2026 Mar 11:e0163525. doi: 10.1128/jvi.01635.
    PubMed         Abstract available
    
    
17. HAN P, Meng Y, Zhang D, Xu Z, et al
    Structural basis of white-tailed deer, Odocoileus virginianus, ACE2 recognizing all the SARS-CoV-2 variants of concern with high affinity.
    J Virol. 2023 Sep 7:e0050523. doi: 10.1128/jvi.00505.
    PubMed         Abstract available
    
    

    
    JAMA

18. WANG L, Nangle SJ, Waller-Pulido A, McMahan K, et al
    Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K.
    JAMA. 2026 Mar 9:e262173. doi: 10.1001/jama.2026.2173.
    PubMed        
    
    
19. JABAGI MJ, Bertrand M, Gabet A, Kolla E, et al
    Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.
    JAMA. 2025 Dec 22:e2524082. doi: 10.1001/jama.2025.24082.
    PubMed         Abstract available
    
    

    
    Lancet

20. NYBERG ST, Frank P, Ahmadi-Abhari S, Pentti J, et al
    Adult obesity and risk of severe infections: a multicohort study with global burden estimates.
    Lancet. 2026 Feb 9:S0140-6736(25)02474-2. doi: 10.1016/S0140-6736(25)02474.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

21. MALONEY P, Reeves EL, Wielgosz K, Price AM, et al
    Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:116-123.
    PubMed         Abstract available
    
    
22. ZHU S, Quint J, Leon TM, Li NJ, et al
    Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - California, October 2025-January 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:124-128.
    PubMed         Abstract available
    
    

    
    N Engl J Med

23. 
    Current and Emerging Approaches to Evaluating Influenza Vaccine Performance.
    N Engl J Med. 2026;394:1144.
    PubMed        
    
    

    
    Pediatrics

24. YAN AP, Archer NM, Arnold D, Hansbury E, et al
    Increasing COVID-19 Vaccination Rates for Children With Sickle Cell Disease.
    Pediatrics. 2023;152:e2022061011.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

25. LOPES R, Lan Y, Chitwood MH, Klaassen F, et al
    Quantifying the spatiotemporal dynamics of the first two epidemic waves of SARS-CoV-2 infections in the United States.
    PLoS Comput Biol. 2026;22:e1013983.
    PubMed         Abstract available
    
    

    
    PLoS Med

26. KAMPITSI CE, Louro J, Mogensen H, Erdmann F, et al
    Childhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study.
    PLoS Med. 2026;23:e1004934.
    PubMed         Abstract available
    
    

    
    PLoS One

27. ALI MA, Sheikh H, Reza MS, Paul TR, et al
    Exploring potential phytocompounds from black cumin as drug molecules against SARS-CoV-2 infections through bioinformatics analysis.
    PLoS One. 2026;21:e0337970.
    PubMed         Abstract available
    
    
28. CASTILLO-NAVARRETE JL, Bustos C, Guzman-Castillo A, Munoz-Reveco L, et al
    Development and validation of the BASE-66 inventory for comprehensive academic stress measurement.
    PLoS One. 2026;21:e0343308.
    PubMed         Abstract available
    
    
29. SOGBESAN A, Bakare AA, Herzig van Wees S, Salako J, et al
    Exploring COVID-19 pandemic perceptions and vaccine uptake among community members and primary healthcare workers in Nigeria: A mixed methods study.
    PLoS One. 2026;21:e0310437.
    PubMed         Abstract available
    
    
30. MESQUITA LO, Dos Santos DF, de Carvalho KMB
    Effect of COVID-19 on mortality due to diabetes mellitus in Brazil: A time series analysis from 2010 to 2023.
    PLoS One. 2026;21:e0344419.
    PubMed         Abstract available
    
    
31. NELSON CE, Kauffman KD, Sakai S, Newbolt T, et al
    Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates.
    PLoS One. 2026;21:e0342849.
    PubMed         Abstract available
    
    
32. DHOUIB W, Kacem M, Belghayeb O, Beji MO, et al
    Serological profile of naive patients affected by the first sars-cov-2 variant: A prospective study.
    PLoS One. 2026;21:e0344308.
    PubMed         Abstract available
    
    
33. DUAH ASUMADU OK, Abiiro GA, Ndago JA, Kanligi DA, et al
    Prevalence and associated factors of health facility delivery during COVID-19 in the Tamale Metropolis of Ghana: Analytical cross-sectional study.
    PLoS One. 2026;21:e0344205.
    PubMed         Abstract available
    
    
34. HU YZ, Qin ZL, Tang W, Hu ZL, et al
    Influence of COVID-19 on postoperative prognosis and pain management.
    PLoS One. 2026;21:e0344211.
    PubMed         Abstract available
    
    
35. ANTUNES L, Nunes B, Nunez O, Martinez-Baz I, et al
    Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24.
    PLoS One. 2026;21:e0343988.
    PubMed         Abstract available
    
    
36. MYERS SP, Tsung C, Chen JC, Gokun Y, et al
    Factors correlated with financial hardship among cancer patients during the COVID-19 pandemic.
    PLoS One. 2026;21:e0342984.
    PubMed         Abstract available
    
    
37. BAEK S, Cho H, Lee S, Yoo M, et al
    Integrated disease model considering mutation-induced infection waves with COVID-19 cases.
    PLoS One. 2026;21:e0341667.
    PubMed         Abstract available
    
    
38. SULIMANY HGH, Almoataz E, Ali A, Faisal F, et al
    Moderating role of CEO expertise on the relationship between capital structure and financial reporting timeliness of Saudi-listed companies.
    PLoS One. 2026;21:e0338840.
    PubMed         Abstract available
    
    
39. MAGALHAES JCN, Chiavegatto Filho ADP
    Predictive divergence in machine learning models for clinical mortality risk: A multicohort study of covid-19 patients.
    PLoS One. 2026;21:e0344354.
    PubMed         Abstract available
    
    
40. BHANDARI B, Thapa P, Timilsina A, Karn RR, et al
    "It becomes more difficult when people don't empathize with us": COVID-19-related stigmatization experienced by survivors in Nepal.
    PLoS One. 2026;21:e0344123.
    PubMed         Abstract available
    
    
41. ATAC O, Aydin V, Peterson LE, Waters TM, et al
    The impact of the COVID-19 pandemic on oral anticoagulation adherence in patients with atrial fibrillation managed in primary care: Results from the PRIME Registry.
    PLoS One. 2026;21:e0344020.
    PubMed         Abstract available
    
    
42. BARTMANN C, Schmidt V, Morz M, Schwab M, et al
    Detection of spike protein in term placentas of COVID-19 vaccinated and/or SARS-CoV-2 infected women.
    PLoS One. 2026;21:e0344185.
    PubMed         Abstract available
    
    
43. CORONADO ZK, Duke M, Rodriguez M, Avelar Portillo LJ, et al
    Latino/a experiences of homelessness in California: Qualitative findings from the California Statewide Study of People Experiencing Homelessness (CASPEH).
    PLoS One. 2026;21:e0344036.
    PubMed         Abstract available
    
    
44. HAMROUNI M, Gupta A, Middleton S, Prosper S, et al
    The Nottingham recovery from COVID-19 research platform (NoRCoRP): Functional, clinical and patient-reported outcomes in adults referred to a post-COVID respiratory service.
    PLoS One. 2026;21:e0344210.
    PubMed         Abstract available
    
    
45. WU C, Paradis NJ
    Near Neutral Selectionist Theories (NNST) for SARS-CoV-2 suggested by the substitution-mutation ratio (c/micro) analysis.
    PLoS One. 2026;21:e0343410.
    PubMed         Abstract available
    
    
46. DIMNJAKOVIC J, Buble T, Poljicanin T, Brborovic H, et al
    Identifying high-risk combinations of metformin during COVID-19.
    PLoS One. 2026;21:e0343979.
    PubMed         Abstract available
    
    
47. KIM TY, Min GJ, Cho SG, Kim S, et al
    Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma.
    PLoS One. 2026;21:e0328666.
    PubMed         Abstract available
    
    
48. RICHARD L, Carter B, Liu M, Nisenbaum R, et al
    Acute healthcare utilization associated with positive SARS-CoV-2 testing or serology among people experiencing homelessness: A prospective cohort study.
    PLoS One. 2026;21:e0343639.
    PubMed         Abstract available
    
    
49. KASULE J, Tonzel JL, Burns N, Hamby T, et al
    COVID-19 knowledge, attitudes, and practices among people vulnerable to HIV in Uganda: A cross-sectional cohort analysis.
    PLoS One. 2026;21:e0343507.
    PubMed         Abstract available
    
    
50. ALOMARI HM, Bani Hani H, Alkhateeb T, Qutaishat D, et al
    Adoption and implementation of teleaudiology as a telehealth model in Jordan and Arab countries: A cross-sectional survey.
    PLoS One. 2026;21:e0343923.
    PubMed         Abstract available
    
    
51. FROLKE SC, Amirkhan KG, van der Bom-Baylon N, van Gils M, et al
    Class switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients.
    PLoS One. 2026;21:e0336320.
    PubMed         Abstract available
    
    
52. CASSIM N, Coetzee LM, da Silva MP, Stevens WS, et al
    Using laboratory data to assess the impact of coronavirus (COVID-19) on reflex cryptococcal antigenaemia (CrAg) testing in South Africa.
    PLoS One. 2023;18:e0292062.
    PubMed         Abstract available
    
    
53. STONEHAM CA, Singh R, De Leon A, Tafelmeyer P, et al
    A cluster of acidic residues in the cytoplasmic domain of SARS-CoV-2 Spike is required for virion-incorporation and infectivity.
    PLoS One. 2026;21:e0340644.
    PubMed         Abstract available
    
    
54. MAZHAR L, Krebs N, Allen SI, Hobkirk AL, et al
    Enhancing recruitment and retention strategies in human tobacco research.
    PLoS One. 2026;21:e0340668.
    PubMed         Abstract available
    
    
55. LAU HC, Sekawi Z, Ching SM, Abu Bakar N, et al
    Effectiveness of the influenza and Tdap vaccination educational module (InTroDuce-Programme) on knowledge and intention for antenatal vaccination: A cluster randomised controlled trial protocol among pregnant women in Malaysian primary care clinics.
    PLoS One. 2026;21:e0344651.
    PubMed         Abstract available
    
    
56. PAN Y, Fan L, Goetz S
    Economic shocks, food insufficiency and mental health: Evidence from the COVID-19 pandemic.
    PLoS One. 2026;21:e0344745.
    PubMed         Abstract available
    
    
57. JONES M, Reilly M, Simanek A, Stewart A, et al
    A randomized assessment of the impact of 'Those Nerdy Girls' newsletters on adult vaccination outcomes.
    PLoS One. 2026;21:e0344258.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

58. ESPINOZA B, Venkatramanan S, Scott Warren A, Lewis BL, et al
    Integrated framework to study genomic surveillance of selective sweeps in multivariants dynamics.
    Proc Natl Acad Sci U S A. 2026;123:e2521031123.
    PubMed         Abstract available
    
    
59. FARAONE JN, Li P, Hong J, Zang J, et al
    Spike destabilization attenuates Mink Cluster 5 SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2026;123:e2528367123.
    PubMed         Abstract available
    
    

    
    Vaccine

60. MESLE MMI, Jorgensen P, Barakat A, Herring BL, et al
    Influenza vaccine recommendations and coverage (2018-2023): a foundation for pandemic preparedness and response.
    Vaccine. 2026;78:128391.
    PubMed         Abstract available
    
    
61. MALLAH N, Pardo-Seco J, Rodriguez-Tenreiro-Sanchez C, Gine-Vazquez I, et al
    Methods and operational framework of GALFLU: Individually randomized pragmatic controlled trial of high- versus standard-dose influenza vaccination in older adults.
    Vaccine. 2026;79:128435.
    PubMed         Abstract available
    
    
62. NUSSBAUM J, Cao X, Railkar RA, Sachs JR, et al
    Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults.
    Vaccine. 2023;41:6488-6501.
    PubMed         Abstract available
    
    
63. MATHUR I, Church R, Ruisch A, Noyes K, et al
    Insights to COVID-19 vaccine delivery: Results from a survey of 27 countries.
    Vaccine. 2023;41:6406-6410.
    PubMed         Abstract available
    
    
64. YESKENDIR A, Gusmanov A, Zhussupov B
    Parental attitudes, beliefs and behaviors toward childhood and COVID-19 vaccines: A countrywide survey conducted in Kazakhstan examining vaccine refusal and hesitancy.
    Vaccine. 2023;41:6548-6557.
    PubMed         Abstract available
    
    
65. DA PENHA GOMES GOUVEA M, Lira Machado KLL, de Oliveira YGP, Moulaz IR, et al
    Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
    Vaccine. 2023;41:6514-6528.
    PubMed         Abstract available
    
    
66. JACOBS ET, Cordova-Marks FM, Farland LV, Ernst KC, et al
    Understanding low COVID-19 booster uptake among US adults.
    Vaccine. 2023;41:6221-6226.
    PubMed         Abstract available
    
    
67. YASUGI M, Nakagama Y, Kaku N, Nitahara Y, et al
    Characteristics of epitope dominance pattern and cross-variant neutralisation in 16 SARS-CoV-2 mRNA vaccine sera.
    Vaccine. 2023;41:6248-6254.
    PubMed         Abstract available
    
    
68. VAUX S, Gautier A, Nassany O, Bonmarin I, et al
    Vaccination acceptability in the French general population and related determinants, 2000-2021.
    Vaccine. 2023;41:6281-6290.
    PubMed         Abstract available
    
    
69. MEERAUS W, Stuurman AL, Durukal I, Conde-Sousa E, et al
    COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron.
    Vaccine. 2023;41:6366-6378.
    PubMed         Abstract available
    
    
70. JI WY, Liu DL, Yu R, Miao L, et al
    Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021.
    Vaccine. 2023;41:6444-6452.
    PubMed         Abstract available
    
    
71. LASSAUNIERE R, Polacek C, Linnea Tingstedt J, Fomsgaard A, et al
    Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine.
    Vaccine. 2023;41:6505-6513.
    PubMed         Abstract available
    
    
72. JALALIZADEH M, Leme PAF, Buosi K, Dionato FAV, et al
    Healthcare Workers (HCWs) and non-HCWs reaction to Bacillus Calmette-Guerin (BCG) in the BATTLE trial.
    Vaccine. 2023;41:6599-6606.
    PubMed         Abstract available
    
    

    
    Virology

73. ORTEGA GRANDA O, Alvarez K, Mate-Perez MJ, Canard B, et al
    Macro1 domain residue F156: A hallmark of SARS-CoV-2 de-MARylation specificity.
    Virology. 2023;587:109845.
    PubMed         Abstract available
    
    
74. HAKIM MS, Widyaningsih SA, Ikram A, Goeijenbier M, et al
    Fundamental concepts of convergent (parallel) evolution in human-pathogenic viruses and their implications for global health.
    Virology. 2026;618:110854.
    PubMed         Abstract available
    
    
75. KIM IH, No JS, Kim JA, Park AK, et al
    Genomic epidemiology of SARS-CoV-2 variants in South Korea between January 2020 and February 2023.
    Virology. 2023;587:109869.
    PubMed         Abstract available
    
    
76. KNANY HR, Elsabbagh SA, Shehata MA, Eldehna WM, et al
    In silico screening of SARS-CoV2 helicase using African natural products: Docking and molecular dynamics approaches.
    Virology. 2023;587:109863.
    PubMed         Abstract available
    
    
77. SHIAU AL, Lee KH, Cho HY, Chuang TH, et al
    Molnupiravir, a ribonucleoside antiviral prodrug against SARS-CoV-2, alters the voltage-gated sodium current and causes adverse events.
    Virology. 2023;587:109865.
    PubMed         Abstract available
    
    
78. PONDE RAA
    Physicochemical effects of emerging exchanges on the spike protein's RBM of the SARS-CoV-2 Omicron subvariants BA.1-BA.5 and its influence on the biological properties and attributes developed by these subvariants.
    Virology. 2023;587:109850.
    PubMed         Abstract available
    
    

    
    Virus Res

79. BONIARDI I, Corona A, Basquin J, Basquin C, et al
    Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function.
    Virus Res. 2023;336:199221.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum